0.437
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
Is ProMIS Neurosciences Inc. stock entering bullish territory2025 Retail Activity & Accurate Buy Signal Notifications - Newser
Using fundamentals and technicals on ProMIS Neurosciences Inc.Quarterly Profit Report & Risk Controlled Swing Alerts - Newser
What’s the recovery path for long term holders of ProMIS Neurosciences Inc.July 2025 Volume & Daily Entry Point Alerts - Newser
Using Ichimoku Cloud for ProMIS Neurosciences Inc. technicalsMarket Sentiment Report & Weekly Sector Rotation Insights - Newser
What institutional flow reveals about ProMIS Neurosciences Inc.2025 Short Interest & Daily Risk Controlled Trade Plans - Newser
Technical analysis overview for ProMIS Neurosciences Inc. stockQuarterly Profit Report & Community Verified Watchlist Alerts - Newser
Applying Wyckoff theory to ProMIS Neurosciences Inc. stockJuly 2025 Patterns & Free Community Consensus Stock Picks - Newser
ProMIS Neurosciences Inc. stock volume spike explainedJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Relative strength of ProMIS Neurosciences Inc. in sector analysisJuly 2025 Final Week & Reliable Momentum Entry Alerts - Newser
Using portfolio simulators with ProMIS Neurosciences Inc. included2025 Volatility Report & Daily Growth Stock Investment Tips - Newser
How to track smart money flows in ProMIS Neurosciences Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
Top chart patterns to watch in ProMIS Neurosciences Inc.July 2025 Big Picture & AI Enhanced Trading Alerts - Newser
Smart tools for monitoring ProMIS Neurosciences Inc.’s price actionFed Meeting & Intraday High Probability Alerts - Newser
ProMIS Neurosciences Inc. stock trend forecastQuarterly Portfolio Summary & Reliable Intraday Trade Plans - Newser
Using economic indicators to assess ProMIS Neurosciences Inc. potentialFed Meeting & Proven Capital Preservation Methods - Newser
Market reaction to ProMIS Neurosciences Inc.’s recent newsMarket Activity Recap & Community Verified Watchlist Alerts - Newser
ProMIS Neurosciences stock price surges in pre market trading as company receives FDA fast track designation for alzheimer’s drug candidate PMN310 - MSN
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss - MSN
Promis Neurosciences (NASDAQ:PMN) and Beam Therapeutics (NASDAQ:BEAM) Critical Survey - Defense World
ProMIS Neurosciences files to sell 28.23M common shares for holders - MSN
ProMIS Neurosciences Plunges 11.63% on SEC Filing - AInvest
ProMIS Neurosciences Inc. stock trend outlook and recovery pathTreasury Yields & Fast Moving Stock Trade Plans - Newser
ProMIS Neurosciences' Secondary Equity Offering: Strategic Motivations and Market Implications - AInvest
What MACD signals say about ProMIS Neurosciences Inc.Quarterly Profit Report & Growth Focused Entry Reports - Newser
ProMIS Neurosciences (PMN) Files Prospectus for Sale of 28.23M S - GuruFocus
ProMIS Neurosciences files prospectus of 28.2 mln common shares offering relates to resale by selling securityholders - MarketScreener
ProMIS Neurosciences' Share Offering and Its Implications for Shareholder Value and Market Perception - AInvest
Does ProMIS Neurosciences Inc. have a sustainable dividend2025 Year in Review & AI Enhanced Market Trend Forecasts - خودرو بانک
Has ProMIS Neurosciences Inc. formed a bullish divergenceWeekly Profit Recap & Pattern Based Trade Signal System - Newser
ProMIS Neurosciences shares fall 7.88% premarket despite positive trial updates and approvals. - AInvest
Will ProMIS Neurosciences Inc. see short term momentumEarnings Beat & Daily Technical Stock Forecast Reports - Newser
Using data tools to time your ProMIS Neurosciences Inc. exitMarket Growth Report & Technical Entry and Exit Alerts - Newser
Sector ETF performance correlation with ProMIS Neurosciences Inc.Risk Management & Consistent Profit Alerts - Newser
Why ProMIS Neurosciences Inc. is moving todayEarnings Overview Summary & Weekly Top Stock Performers List - Newser
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310 - Ariva
Live market analysis of ProMIS Neurosciences Inc.July 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
ProMIS Neurosciences' PMN310: A Safer, Differentiated Alzheimer’s Therapy with Strong Clinical and Regulatory Momentum - AInvest
ProMIS Neurosciences Gets Approval to Advance Alzheimer's Disease Treatment to Final Dose Escalation - MarketScreener
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):